董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christopher A. Viehbacher | 男 | Director,Chief Executive Officer and President | 65 | 2416.67万美元 | 1.28 | 2026-02-06 |
| Stephen A. Sherwin | 男 | Director | 77 | 44.02万美元 | 1.00 | 2026-02-06 |
| Jesus B. Mantas | 男 | Director | 57 | 46.95万美元 | 0.60 | 2026-02-06 |
| Monish Patolawala | 男 | Director | 56 | 44.02万美元 | 未持股 | 2026-02-06 |
| Susan Langer | 女 | Director | 35 | 42.58万美元 | 0.14 | 2026-02-06 |
| Lloyd B. Minor | 男 | Director | 68 | 3.19万美元 | 未持股 | 2026-02-06 |
| William A. Hawkins | 男 | Director | 72 | 47.02万美元 | 0.52 | 2026-02-06 |
| Caroline Dorsa | 女 | Director and Chair of the Board | 66 | 62.98万美元 | 2.48 | 2026-02-06 |
| Eric K. Rowinsky | 男 | Director | 69 | 45.52万美元 | 2.04 | 2026-02-06 |
| Maria C. Freire | 女 | Director | 71 | 44.38万美元 | 0.31 | 2026-02-06 |
| Menelas Pangalos | 男 | Director | 59 | 未披露 | 未持股 | 2026-02-06 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christopher A. Viehbacher | 男 | Director,Chief Executive Officer and President | 65 | 2416.67万美元 | 1.28 | 2026-02-06 |
| Robin C. Kramer | 女 | Chief Financial Officer and Executive Vice President | 60 | 未披露 | 未持股 | 2026-02-06 |
| Rachid Izzar | 男 | Executive Vice President, Global Product Strategy and Commercialization | 51 | 544.78万美元 | 未持股 | 2026-02-06 |
| Nicole Murphy | 女 | Executive Vice President, Pharmaceutical Operations and Technology | 53 | 574.04万美元 | 1.42 | 2026-02-06 |
| Priya Singhal | 女 | Executive Vice President and Head of Development | 58 | 638.77万美元 | 0.92 | 2026-02-06 |
| Jane Grogan | 男 | Executive Vice President and Head of Research | 59 | 未披露 | 未持股 | 2026-02-06 |
| Adam Keeney | 男 | Executive Vice President and Head of Corporate Development | 49 | 未披露 | 未持股 | 2026-02-06 |
| Sean Godbout | 男 | Vice President, Chief Accounting Officer and Global Corporate Controller | 52 | 未披露 | 未持股 | 2026-02-06 |
| Susan H. Alexander | 女 | Chief Legal Officer and Executive Vice President | 69 | 650.58万美元 | 5.63 | 2026-02-06 |
| Ginger Gregory | 女 | Chief Human Resources Officer and Executive Vice President | 58 | 508.03万美元 | 未持股 | 2026-02-06 |
董事简历
中英对照 | 中文 | 英文- Christopher A. Viehbacher
-
Christopher A. Viehbacher，Viehbacher先生自2022年11月起担任Biogen Inc.总裁兼首席执行官、Biogen Inc.董事会成员。在加入Biogen之前，Viehbacher先生曾于2015年至2022年担任总部位于波士顿的投资基金Gurnet Point Capital的管理合伙人。在此之前，Viehbacher先生于2008年至2014年担任赛诺菲全球首席执行官。在加入Sanofi之前，Viehbacher先生在德国、加拿大、法国的GlaxoSmithKline工作了20多年，后来又在美国担任北美制药部门的总裁。Viehbacher先生的职业生涯始于普华永道会计师事务所，并取得了特许会计师资格。Viehbacher先生曾在Vedanta Biosciences，Inc.、Before Brands，Inc.和Crossover Health担任董事会主席。他也是东北大学的董事和斯坦福医学院的研究员委员会成员。上市公司PureTech Health Plc董事会成员。教育，加拿大安大略省Queen's University学士。
Christopher A. Viehbacher has served as President and Chief Executive Officer and member of Board of Directors since November 2022. Prior to joining Biogen, Mr. Viehbacher served as Managing Partner of Gurnet Point Capital, a Boston based investment fund from 2015 to 2022. Prior to that, Mr. Viehbacher served as Global CEO of Sanofi, from 2008 to 2014. Prior to joining Sanofi, Mr. Viehbacher spent over 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the U.S. as president of its North American pharmaceutical division. Mr. Viehbacher began his career with PricewaterhoeCoopers LLP and qualified as a chartered accountant. Mr. Viehbacher previoly served on the board of directors of Vedanta Biosciences, Inc. as chair, BEFORE Brands, Inc., Crossover Health, Sanofi and GlaxoSmithKline. He is also the chair of the board of directors at Braveheart Bio, Inc., a trtee of Northeastern University and a member of the board of fellows at Stanford Medical School.Queen's University in Kingston, Ontario, Canada, B.A. - Christopher A. Viehbacher，Viehbacher先生自2022年11月起担任Biogen Inc.总裁兼首席执行官、Biogen Inc.董事会成员。在加入Biogen之前，Viehbacher先生曾于2015年至2022年担任总部位于波士顿的投资基金Gurnet Point Capital的管理合伙人。在此之前，Viehbacher先生于2008年至2014年担任赛诺菲全球首席执行官。在加入Sanofi之前，Viehbacher先生在德国、加拿大、法国的GlaxoSmithKline工作了20多年，后来又在美国担任北美制药部门的总裁。Viehbacher先生的职业生涯始于普华永道会计师事务所，并取得了特许会计师资格。Viehbacher先生曾在Vedanta Biosciences，Inc.、Before Brands，Inc.和Crossover Health担任董事会主席。他也是东北大学的董事和斯坦福医学院的研究员委员会成员。上市公司PureTech Health Plc董事会成员。教育，加拿大安大略省Queen's University学士。
- Christopher A. Viehbacher has served as President and Chief Executive Officer and member of Board of Directors since November 2022. Prior to joining Biogen, Mr. Viehbacher served as Managing Partner of Gurnet Point Capital, a Boston based investment fund from 2015 to 2022. Prior to that, Mr. Viehbacher served as Global CEO of Sanofi, from 2008 to 2014. Prior to joining Sanofi, Mr. Viehbacher spent over 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the U.S. as president of its North American pharmaceutical division. Mr. Viehbacher began his career with PricewaterhoeCoopers LLP and qualified as a chartered accountant. Mr. Viehbacher previoly served on the board of directors of Vedanta Biosciences, Inc. as chair, BEFORE Brands, Inc., Crossover Health, Sanofi and GlaxoSmithKline. He is also the chair of the board of directors at Braveheart Bio, Inc., a trtee of Northeastern University and a member of the board of fellows at Stanford Medical School.Queen's University in Kingston, Ontario, Canada, B.A.
- Stephen A. Sherwin
-
Stephen A. Sherwin自2015年9月以来，Sherwin一直担任Neon Therapeutics, Inc.的董事会成员。Sherwin博士是旧金山加利福尼亚大学的临床医学教授，扎克伯格旧金山综合医院血液肿瘤科的一名志愿者主治医师。Sherwin博士目前也是Third Rock的风险合伙人，也是帕克癌症免疫治疗研究所科学指导委员会的成员。Sherwin博士曾于2001年担任Ceregene，Inc.的联合创始人和董事长，直到2013年被Sangamo Biosciences，Inc.收购。在此之前，Sherwin博士于1990年担任Cell Genesys，Inc.的董事长兼首席执行官，这是一家癌症免疫治疗公司，直到2009年与ANI Pharmaceuticals合并，公司前身为BioSante Pharmaceuticals，Inc.舍温博士还是安进公司于2006年收购的抗体公司Abgenix的联合创始人和董事长。舍温博士在过去五年中目前在Aduro Biotech，Inc.、Biogen，Inc.和Neurocrine Biosciences，Inc.的董事会任职，Sherwin博士还担任BiangnTe制药公司的董事，直到与阿尼制药公司合并，在2013个RigelP药学公司，VICA公司和VelaSTEM公司。Sherwin博士持有哈佛医学院的医学博士，以及生物学学士学位，来自耶鲁大学的优等生。于2025年08月26日获委任为信达生物制药独立非执行董事、战略委员会委员。
Stephen A. Sherwin,is a Clinical Professor of Medicine at UCSF (since 2010) and Volunteer Attending Physician at Zuckerberg San Francisco General Hospital. As an Advisory Partner at Third Rock Ventures (since 2016), he co-founded and chaired Ceregene (acquired by Sangamo, 2001–2013) and Abgenix (acquired by Amgen, 1996–2006), and was CEO of Cell Genesys (merged with BioSante, 1994–2009). He serves on the board of Neurocrine Biosciences (since 1999) and previously directed Epiphany Technology Acquisition Corp. (2022–2023), Bios Special Acquisition Corp. (2021–2023), and Aduro Biotech (2015–2020). He holds a BA in Biology from Yale and an MD from Harvard Medical School. - Stephen A. Sherwin自2015年9月以来，Sherwin一直担任Neon Therapeutics, Inc.的董事会成员。Sherwin博士是旧金山加利福尼亚大学的临床医学教授，扎克伯格旧金山综合医院血液肿瘤科的一名志愿者主治医师。Sherwin博士目前也是Third Rock的风险合伙人，也是帕克癌症免疫治疗研究所科学指导委员会的成员。Sherwin博士曾于2001年担任Ceregene，Inc.的联合创始人和董事长，直到2013年被Sangamo Biosciences，Inc.收购。在此之前，Sherwin博士于1990年担任Cell Genesys，Inc.的董事长兼首席执行官，这是一家癌症免疫治疗公司，直到2009年与ANI Pharmaceuticals合并，公司前身为BioSante Pharmaceuticals，Inc.舍温博士还是安进公司于2006年收购的抗体公司Abgenix的联合创始人和董事长。舍温博士在过去五年中目前在Aduro Biotech，Inc.、Biogen，Inc.和Neurocrine Biosciences，Inc.的董事会任职，Sherwin博士还担任BiangnTe制药公司的董事，直到与阿尼制药公司合并，在2013个RigelP药学公司，VICA公司和VelaSTEM公司。Sherwin博士持有哈佛医学院的医学博士，以及生物学学士学位，来自耶鲁大学的优等生。于2025年08月26日获委任为信达生物制药独立非执行董事、战略委员会委员。
- Stephen A. Sherwin,is a Clinical Professor of Medicine at UCSF (since 2010) and Volunteer Attending Physician at Zuckerberg San Francisco General Hospital. As an Advisory Partner at Third Rock Ventures (since 2016), he co-founded and chaired Ceregene (acquired by Sangamo, 2001–2013) and Abgenix (acquired by Amgen, 1996–2006), and was CEO of Cell Genesys (merged with BioSante, 1994–2009). He serves on the board of Neurocrine Biosciences (since 1999) and previously directed Epiphany Technology Acquisition Corp. (2022–2023), Bios Special Acquisition Corp. (2021–2023), and Aduro Biotech (2015–2020). He holds a BA in Biology from Yale and an MD from Harvard Medical School.
- Jesus B. Mantas
-
Jesus B. Mantas 是负责IBM业务转型服务部门的全球管理合伙人，他还负责IBM咨询企业发展。Mantas先生是IBM执行绩效团队、IBM执行技术团队和IBM主席加速团队的成员，并且是IBM西班牙裔多元化委员会的名誉主席。他在世界经济论坛的全球人工智能委员会和HITEC的董事会任职，HITEC是一家专注于发展和推进西班牙裔高管在科技行业职业生涯的非营利组织。他是Benhamou Global Ventures Fund IV的有限合伙人，Benhamou Global Ventures Fund IV是一家专注于数字化转型的早期公司的投资基金，并且是西班牙裔主导的早期公司的积极投资者。从2002年到2016年，Mantas先生领导IBM的商业咨询部门，该部门是世界上最大的咨询机构之一。此前，他曾担任IBM全球流程服务和业务服务部门在拉丁美洲的领导职务，此前他曾担任北美副总裁的多个领导职位。在加入IBM之前，Mantas先生是普华永道咨询公司的合伙人、加州大学欧文分校管理研究生院的兼职教授和西班牙空军的一名军官。
Jesus B. Mantas,served as Global Managing Partner of IBM Global Business Services (2022–2025) after a distinguished 20-year career at IBM (2002–2022), where he held leadership roles including Global Managing Partner for Strategy, Innovation and Corporate Development, Global Managing Partner for IBM Business Consulting, and General Manager for IBM Business Process Outsourcing. Earlier, he was a Partner in PricewaterhouseCoopers Consulting's High Technology Practice (1997–2002) and an Adjunct Professor at UC Irvine's Paul Merage School of Business (1997–2001). His career began as a Second Lieutenant in the Spanish Air Force (1993). He holds a B.S. in Telecommunications – Software Engineering and a Degree in Business Administration from Universidad Politécnica de Madrid, complemented by executive education in Corporate Governance from Harvard Business School. - Jesus B. Mantas 是负责IBM业务转型服务部门的全球管理合伙人，他还负责IBM咨询企业发展。Mantas先生是IBM执行绩效团队、IBM执行技术团队和IBM主席加速团队的成员，并且是IBM西班牙裔多元化委员会的名誉主席。他在世界经济论坛的全球人工智能委员会和HITEC的董事会任职，HITEC是一家专注于发展和推进西班牙裔高管在科技行业职业生涯的非营利组织。他是Benhamou Global Ventures Fund IV的有限合伙人，Benhamou Global Ventures Fund IV是一家专注于数字化转型的早期公司的投资基金，并且是西班牙裔主导的早期公司的积极投资者。从2002年到2016年，Mantas先生领导IBM的商业咨询部门，该部门是世界上最大的咨询机构之一。此前，他曾担任IBM全球流程服务和业务服务部门在拉丁美洲的领导职务，此前他曾担任北美副总裁的多个领导职位。在加入IBM之前，Mantas先生是普华永道咨询公司的合伙人、加州大学欧文分校管理研究生院的兼职教授和西班牙空军的一名军官。
- Jesus B. Mantas,served as Global Managing Partner of IBM Global Business Services (2022–2025) after a distinguished 20-year career at IBM (2002–2022), where he held leadership roles including Global Managing Partner for Strategy, Innovation and Corporate Development, Global Managing Partner for IBM Business Consulting, and General Manager for IBM Business Process Outsourcing. Earlier, he was a Partner in PricewaterhouseCoopers Consulting's High Technology Practice (1997–2002) and an Adjunct Professor at UC Irvine's Paul Merage School of Business (1997–2001). His career began as a Second Lieutenant in the Spanish Air Force (1993). He holds a B.S. in Telecommunications – Software Engineering and a Degree in Business Administration from Universidad Politécnica de Madrid, complemented by executive education in Corporate Governance from Harvard Business School.
- Monish Patolawala
-
Monish Patolawala，首席财务官，医疗保健和副总裁，运营转型，通用电气，2019-2020年。首席财务官，医疗保健，通用电气，2015-2019年。
Monish Patolawala,currently serves as Chief Financial Officer of ADM (since 2024), having previously held the dual role of President and CFO at 3M Company (2020–2024). His 26-year tenure at General Electric (1994–2020) included serving as CFO of GE Healthcare (2015–2020) and progressing through various financial leadership positions. A qualified finance professional, he holds certifications as a Chartered Accountant (Institute of Chartered Accountants of India) and Cost and Works Accountant (Institute of Cost and Works Accountants of India), and earned his B.Com from St. Joseph's College of Commerce in Bangalore, India. - Monish Patolawala，首席财务官，医疗保健和副总裁，运营转型，通用电气，2019-2020年。首席财务官，医疗保健，通用电气，2015-2019年。
- Monish Patolawala,currently serves as Chief Financial Officer of ADM (since 2024), having previously held the dual role of President and CFO at 3M Company (2020–2024). His 26-year tenure at General Electric (1994–2020) included serving as CFO of GE Healthcare (2015–2020) and progressing through various financial leadership positions. A qualified finance professional, he holds certifications as a Chartered Accountant (Institute of Chartered Accountants of India) and Cost and Works Accountant (Institute of Cost and Works Accountants of India), and earned his B.Com from St. Joseph's College of Commerce in Bangalore, India.
- Susan Langer
-
Susan Langer，自2021年起担任Souffle Therapeutics的总裁兼首席商务官。Kojin Therapeutics创始总裁（2020 - 2021）。Paratus Sciences首席商务官（2021 - 2023）。Guava Partners董事（自2021年起）。投资合伙人，Old Silver VC LLC（2020 - 2023）。Biogen公司战略主管和其他职位（2013 - 2019）Science & Technology Studies from Cornell University硕士。
Susan Langer,currently serves as President and Chief Business Officer of Souffle Therapeutics (since 2021) and as Director of Guava Partners (since 2021). She was Founding President of Kojin Therapeutics (2020–2021) and Chief Business Officer of Paratus Sciences (2021–2023). Previously, she was a Venture Partner at Old Silver VC LLC (2020–2023) and held leadership roles at Biogen (2013–2019), including Head of Corporate Strategy. She holds a B.A. in Science & Technology Studies from Cornell University. - Susan Langer，自2021年起担任Souffle Therapeutics的总裁兼首席商务官。Kojin Therapeutics创始总裁（2020 - 2021）。Paratus Sciences首席商务官（2021 - 2023）。Guava Partners董事（自2021年起）。投资合伙人，Old Silver VC LLC（2020 - 2023）。Biogen公司战略主管和其他职位（2013 - 2019）Science & Technology Studies from Cornell University硕士。
- Susan Langer,currently serves as President and Chief Business Officer of Souffle Therapeutics (since 2021) and as Director of Guava Partners (since 2021). She was Founding President of Kojin Therapeutics (2020–2021) and Chief Business Officer of Paratus Sciences (2021–2023). Previously, she was a Venture Partner at Old Silver VC LLC (2020–2023) and held leadership roles at Biogen (2013–2019), including Head of Corporate Strategy. She holds a B.A. in Science & Technology Studies from Cornell University.
- Lloyd B. Minor
-
Lloyd B. Minor，自2012年起担任斯坦福大学医学院院长，自2023年起担任斯坦福大学医学事务副校长。此前，他曾担任约翰斯·霍普金斯大学教务长兼学术事务高级副校长（2009-2012年），以及约翰斯·霍普金斯大学耳鼻喉科-头颈外科系主任（2003-2009年）。他拥有布朗大学的理学学士学位和医学博士学位。
Lloyd B. Minor,is currently the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine, a position he has held since 2012. In addition to being the Dean of the School of Medicine, he became the Vice President for Medical Affairs at Stanford University in August 2023. Dr. Minor has also been a professor of Otolaryngology—Head and Neck Surgery and a professor of Neurobiology and Bioengineering, by courtesy, since 2012. Prior to 2012, Dr. Minor served as the Provost and Senior Vice President for Academic Affairs at Johns Hopkins University from 2009 to 2012. Dr. Minor began his career at Johns Hopkins School of Medicine in the Department of Otolaryngology—Head and Neck Surgery as a Professor from 1993 to 2003, before serving as department's Andelot Professor and Director (Chair) from 2003 to 2009. Dr. Minor has served as a member of the board of directors of Biogen, a global pharmaceutical company, since 2024. Dr. Minor holds a Bachelor of Science in Biology and a Doctor of Medicine from Brown University. In 2012, Dr. Minor was elected to the National Academy of Medicine, formerly the Institute of Medicine. - Lloyd B. Minor，自2012年起担任斯坦福大学医学院院长，自2023年起担任斯坦福大学医学事务副校长。此前，他曾担任约翰斯·霍普金斯大学教务长兼学术事务高级副校长（2009-2012年），以及约翰斯·霍普金斯大学耳鼻喉科-头颈外科系主任（2003-2009年）。他拥有布朗大学的理学学士学位和医学博士学位。
- Lloyd B. Minor,is currently the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine, a position he has held since 2012. In addition to being the Dean of the School of Medicine, he became the Vice President for Medical Affairs at Stanford University in August 2023. Dr. Minor has also been a professor of Otolaryngology—Head and Neck Surgery and a professor of Neurobiology and Bioengineering, by courtesy, since 2012. Prior to 2012, Dr. Minor served as the Provost and Senior Vice President for Academic Affairs at Johns Hopkins University from 2009 to 2012. Dr. Minor began his career at Johns Hopkins School of Medicine in the Department of Otolaryngology—Head and Neck Surgery as a Professor from 1993 to 2003, before serving as department's Andelot Professor and Director (Chair) from 2003 to 2009. Dr. Minor has served as a member of the board of directors of Biogen, a global pharmaceutical company, since 2024. Dr. Minor holds a Bachelor of Science in Biology and a Doctor of Medicine from Brown University. In 2012, Dr. Minor was elected to the National Academy of Medicine, formerly the Institute of Medicine.
- William A. Hawkins
-
William A. Hawkins自2007年3月以来是Medtronic的董事，自2008年8月以来担任董事长兼首席执行官。他自2007年8月以来担任Medtronic的总裁兼首席执行官，之前从2004年5月到2007年8月担任Medtronic的总裁兼首席运营官。他从2002年1月到2004年5月担任Medtronic Vascular的高级副总裁和总裁。他从1998年到2002年担任Novoste Corporation的总裁兼首席执行官。他服务于杜克大学工程学院（the Duke University School of Engineering）的监事会和the Guthrie Theater以及Minnesota Foundation大学的董事会。在过去的五年里，他还担任Deluxe Corporation的董事。
William A. Hawkins,is currently a Senior Advisor at EW Healthcare Partners (since 2017),including President and CEO of Immucor (2011–2015), Chairman and CEO of Medtronic (2002–2011), and President and CEO of Novoste Corporation (1998–2001). He serves as Chair of Bioventus, Inc. (since 2016) and on the board of MiMedx Group, Inc. (since 2020), with prior directorship at Avanos Medical (2015–2021). His private company board engagements include Virtue Labs, Enterra, Lacuna Medical, Critec Medical Corp., and Baebies, Inc. He holds a B.Sc. in Electrical and Biomedical Engineering from Duke University and an MBA from the University of Virginia's Darden School, and is a member of the National Academy of Engineering and AIMBE College of Fellows. - William A. Hawkins自2007年3月以来是Medtronic的董事，自2008年8月以来担任董事长兼首席执行官。他自2007年8月以来担任Medtronic的总裁兼首席执行官，之前从2004年5月到2007年8月担任Medtronic的总裁兼首席运营官。他从2002年1月到2004年5月担任Medtronic Vascular的高级副总裁和总裁。他从1998年到2002年担任Novoste Corporation的总裁兼首席执行官。他服务于杜克大学工程学院（the Duke University School of Engineering）的监事会和the Guthrie Theater以及Minnesota Foundation大学的董事会。在过去的五年里，他还担任Deluxe Corporation的董事。
- William A. Hawkins,is currently a Senior Advisor at EW Healthcare Partners (since 2017),including President and CEO of Immucor (2011–2015), Chairman and CEO of Medtronic (2002–2011), and President and CEO of Novoste Corporation (1998–2001). He serves as Chair of Bioventus, Inc. (since 2016) and on the board of MiMedx Group, Inc. (since 2020), with prior directorship at Avanos Medical (2015–2021). His private company board engagements include Virtue Labs, Enterra, Lacuna Medical, Critec Medical Corp., and Baebies, Inc. He holds a B.Sc. in Electrical and Biomedical Engineering from Duke University and an MBA from the University of Virginia's Darden School, and is a member of the National Academy of Engineering and AIMBE College of Fellows.
- Caroline Dorsa
-
Caroline Dorsa 2009年4月到现在担任PSEG的执行副总裁和首席财务官；2009年4月到现在担任执行副总裁和首席财务官（动力）；2009年4月到现在担任执行副总裁和首席财务官（PSE＆G）；2009年4月到现在担任首席财务官（能源控股）；2009年4月到现在担任执行副总裁和首席财务官（服务）；2008年1月到2009年4月担任全球人类健康策略和集成（默克股份有限公司）的高级副总裁；2007年11月到2008年1月担任高级副总裁和首席财务官（Gilead科学股份有限公司）；2007年2月到2007年11月担任高级副总裁首席财务官（Avaya股份有限公司）。
Caroline Dorsa served as the Executive Vice President and CFO of Public Service Enterprise Group, a diversified energy company, from April 2009 until her retirement in October 2015, and served on its board of directors from February 2003 to April 2009. She also served in numero senior management positions at Merck, Gilead Sciences, and Avaya prior to joining Public Service Enterprise Group. Ms. Dorsa previoly served as a trtee on the boards of the Goldman Sachs Asset Management ETF, Closed End Funds, and Intellia Therapeutics, Inc. Ms. Dorsa will be retiring as a director on the board of Biogen Inc. effective June 9, 2026. - Caroline Dorsa 2009年4月到现在担任PSEG的执行副总裁和首席财务官；2009年4月到现在担任执行副总裁和首席财务官（动力）；2009年4月到现在担任执行副总裁和首席财务官（PSE＆G）；2009年4月到现在担任首席财务官（能源控股）；2009年4月到现在担任执行副总裁和首席财务官（服务）；2008年1月到2009年4月担任全球人类健康策略和集成（默克股份有限公司）的高级副总裁；2007年11月到2008年1月担任高级副总裁和首席财务官（Gilead科学股份有限公司）；2007年2月到2007年11月担任高级副总裁首席财务官（Avaya股份有限公司）。
- Caroline Dorsa served as the Executive Vice President and CFO of Public Service Enterprise Group, a diversified energy company, from April 2009 until her retirement in October 2015, and served on its board of directors from February 2003 to April 2009. She also served in numero senior management positions at Merck, Gilead Sciences, and Avaya prior to joining Public Service Enterprise Group. Ms. Dorsa previoly served as a trtee on the boards of the Goldman Sachs Asset Management ETF, Closed End Funds, and Intellia Therapeutics, Inc. Ms. Dorsa will be retiring as a director on the board of Biogen Inc. effective June 9, 2026.
- Eric K. Rowinsky
-
Eric K. Rowinsky担任执行副总裁、首席医疗官以及研发部负责人。Rowinsk博士先前在英克隆系统公司（ImClone Systems）担任首席医疗管。Rowinsk博士在临床试验管理领域以及肿瘤类药物研发领域具有超过25年的经验，包括使爱必妥（Erbitux）通过食品及药物管理局（Food and Drug Administration）认证的工作，其中用于治疗脑、颈以及结肠癌；以及通过临床开发，推进其他8种生物疗法。以上工作都是在英克隆系统公司完成的。他还在各类癌症疗法药物的研发以及注册上起到积极作用，上述疗法药物包括紫杉醇、多烯紫杉醇、伊立替康、拓扑替康、埃罗替尼、吉非替尼、帕尼单抗、拉帕替尼以及西罗莫司脂化物。Rowinsky博士目前在百健艾迪（Biogen IDEC）股份有限公司以及其他上市生物制药公司董事会工作，同时踏实纽约州大学医学院的副教授。他在约翰·霍普金斯医院完成了内科肿瘤研究项目。Rowinsky博士是约翰·霍普金斯医院肿瘤科副教授，随后成为临床研究负责人以及癌症疗法与研究中心（Cancer Therapy and Research Center）药物研发协会（Institute for Drug Development）的董事，该中心位于在德克萨斯州圣安东尼。
Eric K. Rowinsky,currently serves as President of privately held life science company Inspima (since 2015) and was its Executive Chairman (2016–2021). His recent leadership roles include Chief Medical Officer of Hummingbird Biotherapeutics (2020–2023) and Chief Scientific Officer of Clearpath Development (2016–2021). Previously, he was Head of R&D/CMO at Siemline Therapeutics (2012–2015), CEO of Primrose Therapeutics (2010–2011), and EVP/CMO at ImClone Systems (2005–2010). An accomplished oncologist, he directed the Cancer Therapy & Research Center's Institute for Drug Development (1996–2004) and was Associate Professor of Oncology at Johns Hopkins (1988–1996). He serves on boards of Purple Biotech Ltd. (since 2019) and Verastem, Inc. (since 2017), with prior directorship at Fortress Biotech (2010–2024). He holds a BA in Liberal Arts from NYU and MD from Vanderbilt University, with advisory roles including the National Cancer Institute's Scientific Counselors. - Eric K. Rowinsky担任执行副总裁、首席医疗官以及研发部负责人。Rowinsk博士先前在英克隆系统公司（ImClone Systems）担任首席医疗管。Rowinsk博士在临床试验管理领域以及肿瘤类药物研发领域具有超过25年的经验，包括使爱必妥（Erbitux）通过食品及药物管理局（Food and Drug Administration）认证的工作，其中用于治疗脑、颈以及结肠癌；以及通过临床开发，推进其他8种生物疗法。以上工作都是在英克隆系统公司完成的。他还在各类癌症疗法药物的研发以及注册上起到积极作用，上述疗法药物包括紫杉醇、多烯紫杉醇、伊立替康、拓扑替康、埃罗替尼、吉非替尼、帕尼单抗、拉帕替尼以及西罗莫司脂化物。Rowinsky博士目前在百健艾迪（Biogen IDEC）股份有限公司以及其他上市生物制药公司董事会工作，同时踏实纽约州大学医学院的副教授。他在约翰·霍普金斯医院完成了内科肿瘤研究项目。Rowinsky博士是约翰·霍普金斯医院肿瘤科副教授，随后成为临床研究负责人以及癌症疗法与研究中心（Cancer Therapy and Research Center）药物研发协会（Institute for Drug Development）的董事，该中心位于在德克萨斯州圣安东尼。
- Eric K. Rowinsky,currently serves as President of privately held life science company Inspima (since 2015) and was its Executive Chairman (2016–2021). His recent leadership roles include Chief Medical Officer of Hummingbird Biotherapeutics (2020–2023) and Chief Scientific Officer of Clearpath Development (2016–2021). Previously, he was Head of R&D/CMO at Siemline Therapeutics (2012–2015), CEO of Primrose Therapeutics (2010–2011), and EVP/CMO at ImClone Systems (2005–2010). An accomplished oncologist, he directed the Cancer Therapy & Research Center's Institute for Drug Development (1996–2004) and was Associate Professor of Oncology at Johns Hopkins (1988–1996). He serves on boards of Purple Biotech Ltd. (since 2019) and Verastem, Inc. (since 2017), with prior directorship at Fortress Biotech (2010–2024). He holds a BA in Liberal Arts from NYU and MD from Vanderbilt University, with advisory roles including the National Cancer Institute's Scientific Counselors.
- Maria C. Freire
-
Maria C. Freire， 2012年11月至2021年9月，她担任the Foundation for the National Institutes of Health的总裁、执行董事和董事会成员。从2008年3月到2012年11月，她担任the Albert and Mary Lasker Foundation的总裁和董事会成员。加入Lasker Foundation之前，她曾担任the Global Alliance for TB Drug Development的总裁兼首席执行官（2001年至2008年），以及the National Institutes of Health的技术转移办公室主任（1995年至2001年）。她曾任职于许多国家和国际组织的董事会，包括美国食品和药物管理局科学委员会、世界卫生组织知识产权、创新和公共卫生委员会以及联合国秘书长药品获取问题高级别小组。她还担任Koneksa Health（一家私营公司，开发、测试和验证用于临床试验的数字生物标志物）的董事会成员。她也是美国国家医学院和外交关系委员会的成员，她是许多奖项的获得者，包括2017年Gold Stevie Award“年度女性”，美国卫生和人类服务部部长杰出服务奖，Arthur S. Fleming奖和Bayh-Dole奖。她持 Virginia大学的生物物理学博士学位，以及Peruana Cayetano Heredia大学（位于Lima, Peru。）的学士学位。
Maria C. Freire has served as a director since April 2012. Dr. Freire is Founder and Principal of The Freire Group, a strategic advisory firm serving life sciences organizations. She currently serves on the boards of Biogen (NASDAQ: BIIB), Exelixis, Inc. (NASDAQ: EXEL), and Keystone Symposia on Molecular and Cell Biology. On February 11, 2026, Dr. Freire was elected to serve as Chair of the Board of Directors of Biogen effective following Biogen's 2026 annual meeting of stockholders in June 2026. She is a member of the U.S. National Academy of Medicine and the Council on Foreign Relations. Dr. Freire is a senior life sciences executive with a proven record of leading and governing complex, mission critical organizations across biotechnology and global health. Dr. Freire has expertise in drug development, biomedical innovation, technology commercialization, and science policy, with a focus on disciplined strategy, long term value creation, and patient centric outcomes. Dr. Freire served as President and Executive Director of the FNIH from 2012 to 2021, where she led a Congressionally authorized organization that builds and manages large scale public private partnerships advancing research and clinical development across oncology, neurodegenerative diseases, autoimmune disorders, and infectious diseases. Earlier, as President and Chief Executive Officer of the Global Alliance for TB Drug Development (TB Alliance), she built and led a sustainable drug development organization, spearheading the advancement of pretomanid from preclinical research to clinical trials. Pretomanid is now approved for the treatment of multidrug resistant tuberculosis. Dr. Freire also served as President and as a member of the board of directors of the Albert and Mary Lasker Foundation, stewarding the internationally recognized Lasker Awards and advocating for sustained investment in biomedical research. Earlier in her career, she directed the Office of Technology Transfer at the National Institutes of Health and served as a commissioner on the World Health Organization's Commission on Intellectual Property Rights, Innovation and Public Health. Her awards include the Department of Health and Human Services Secretary's Award for Distinguished Service, the Arthur S. Flemming Award, the Bayh Dole Award, the 2017 Washington Business Journal's "Women Who Mean Business" Award, the 2017 Gold Stevie Award for "Woman of the Year," and NonProfit PRO's 2019 "Executive of the Year" Award. Dr. Freire holds a PhD in Biophysics from the University of Virginia and a Bachelor of Science degree from Universidad Peruana Cayetano Heredia in Lima, Peru. - Maria C. Freire， 2012年11月至2021年9月，她担任the Foundation for the National Institutes of Health的总裁、执行董事和董事会成员。从2008年3月到2012年11月，她担任the Albert and Mary Lasker Foundation的总裁和董事会成员。加入Lasker Foundation之前，她曾担任the Global Alliance for TB Drug Development的总裁兼首席执行官（2001年至2008年），以及the National Institutes of Health的技术转移办公室主任（1995年至2001年）。她曾任职于许多国家和国际组织的董事会，包括美国食品和药物管理局科学委员会、世界卫生组织知识产权、创新和公共卫生委员会以及联合国秘书长药品获取问题高级别小组。她还担任Koneksa Health（一家私营公司，开发、测试和验证用于临床试验的数字生物标志物）的董事会成员。她也是美国国家医学院和外交关系委员会的成员，她是许多奖项的获得者，包括2017年Gold Stevie Award“年度女性”，美国卫生和人类服务部部长杰出服务奖，Arthur S. Fleming奖和Bayh-Dole奖。她持 Virginia大学的生物物理学博士学位，以及Peruana Cayetano Heredia大学（位于Lima, Peru。）的学士学位。
- Maria C. Freire has served as a director since April 2012. Dr. Freire is Founder and Principal of The Freire Group, a strategic advisory firm serving life sciences organizations. She currently serves on the boards of Biogen (NASDAQ: BIIB), Exelixis, Inc. (NASDAQ: EXEL), and Keystone Symposia on Molecular and Cell Biology. On February 11, 2026, Dr. Freire was elected to serve as Chair of the Board of Directors of Biogen effective following Biogen's 2026 annual meeting of stockholders in June 2026. She is a member of the U.S. National Academy of Medicine and the Council on Foreign Relations. Dr. Freire is a senior life sciences executive with a proven record of leading and governing complex, mission critical organizations across biotechnology and global health. Dr. Freire has expertise in drug development, biomedical innovation, technology commercialization, and science policy, with a focus on disciplined strategy, long term value creation, and patient centric outcomes. Dr. Freire served as President and Executive Director of the FNIH from 2012 to 2021, where she led a Congressionally authorized organization that builds and manages large scale public private partnerships advancing research and clinical development across oncology, neurodegenerative diseases, autoimmune disorders, and infectious diseases. Earlier, as President and Chief Executive Officer of the Global Alliance for TB Drug Development (TB Alliance), she built and led a sustainable drug development organization, spearheading the advancement of pretomanid from preclinical research to clinical trials. Pretomanid is now approved for the treatment of multidrug resistant tuberculosis. Dr. Freire also served as President and as a member of the board of directors of the Albert and Mary Lasker Foundation, stewarding the internationally recognized Lasker Awards and advocating for sustained investment in biomedical research. Earlier in her career, she directed the Office of Technology Transfer at the National Institutes of Health and served as a commissioner on the World Health Organization's Commission on Intellectual Property Rights, Innovation and Public Health. Her awards include the Department of Health and Human Services Secretary's Award for Distinguished Service, the Arthur S. Flemming Award, the Bayh Dole Award, the 2017 Washington Business Journal's "Women Who Mean Business" Award, the 2017 Gold Stevie Award for "Woman of the Year," and NonProfit PRO's 2019 "Executive of the Year" Award. Dr. Freire holds a PhD in Biophysics from the University of Virginia and a Bachelor of Science degree from Universidad Peruana Cayetano Heredia in Lima, Peru.
- Menelas Pangalos
-
Menelas Pangalos，在担任早期研发执行副总裁（2010-2018）之后，曾担任阿斯利康生物制药研发执行副总裁（2019-2024）。他之前的职位包括辉瑞（Pfizer）的高级副总裁（2008-2010）和惠氏（Wyeth）的神经科学副总裁（2003-2008）。他是一位杰出的科学家，是英国皇家学会、英国医学科学院、英国皇家生物学会和剑桥克莱尔霍尔学会的会员。他于2024年加入Absci公司董事会。他持有伦敦帝国理工学院生物化学和分子生物学学士学位，以及伦敦大学学院神经药理学博士学位。
Menelas Pangalos,served as Executive Vice President of Biopharmaceuticals R&D at AstraZeneca (2019–2024) after leading as EVP of Early R&D (2010–2018). His prior roles include SVP at Pfizer (2008–2010) and VP of Neuroscience at Wyeth (2003–2008). A distinguished scientist, he is a Fellow of the Royal Society, Academy of Medical Sciences, Royal Society of Biology, and Clare Hall, Cambridge. He joined Absci Corporation's board in 2024. He holds a BSc in Biochemistry and Molecular Biology from Imperial College London and a PhD in Neuropharmacology from University College London. - Menelas Pangalos，在担任早期研发执行副总裁（2010-2018）之后，曾担任阿斯利康生物制药研发执行副总裁（2019-2024）。他之前的职位包括辉瑞（Pfizer）的高级副总裁（2008-2010）和惠氏（Wyeth）的神经科学副总裁（2003-2008）。他是一位杰出的科学家，是英国皇家学会、英国医学科学院、英国皇家生物学会和剑桥克莱尔霍尔学会的会员。他于2024年加入Absci公司董事会。他持有伦敦帝国理工学院生物化学和分子生物学学士学位，以及伦敦大学学院神经药理学博士学位。
- Menelas Pangalos,served as Executive Vice President of Biopharmaceuticals R&D at AstraZeneca (2019–2024) after leading as EVP of Early R&D (2010–2018). His prior roles include SVP at Pfizer (2008–2010) and VP of Neuroscience at Wyeth (2003–2008). A distinguished scientist, he is a Fellow of the Royal Society, Academy of Medical Sciences, Royal Society of Biology, and Clare Hall, Cambridge. He joined Absci Corporation's board in 2024. He holds a BSc in Biochemistry and Molecular Biology from Imperial College London and a PhD in Neuropharmacology from University College London.
高管简历
中英对照 | 中文 | 英文- Christopher A. Viehbacher
Christopher A. Viehbacher，Viehbacher先生自2022年11月起担任Biogen Inc.总裁兼首席执行官、Biogen Inc.董事会成员。在加入Biogen之前，Viehbacher先生曾于2015年至2022年担任总部位于波士顿的投资基金Gurnet Point Capital的管理合伙人。在此之前，Viehbacher先生于2008年至2014年担任赛诺菲全球首席执行官。在加入Sanofi之前，Viehbacher先生在德国、加拿大、法国的GlaxoSmithKline工作了20多年，后来又在美国担任北美制药部门的总裁。Viehbacher先生的职业生涯始于普华永道会计师事务所，并取得了特许会计师资格。Viehbacher先生曾在Vedanta Biosciences，Inc.、Before Brands，Inc.和Crossover Health担任董事会主席。他也是东北大学的董事和斯坦福医学院的研究员委员会成员。上市公司PureTech Health Plc董事会成员。教育，加拿大安大略省Queen's University学士。
Christopher A. Viehbacher has served as President and Chief Executive Officer and member of Board of Directors since November 2022. Prior to joining Biogen, Mr. Viehbacher served as Managing Partner of Gurnet Point Capital, a Boston based investment fund from 2015 to 2022. Prior to that, Mr. Viehbacher served as Global CEO of Sanofi, from 2008 to 2014. Prior to joining Sanofi, Mr. Viehbacher spent over 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the U.S. as president of its North American pharmaceutical division. Mr. Viehbacher began his career with PricewaterhoeCoopers LLP and qualified as a chartered accountant. Mr. Viehbacher previoly served on the board of directors of Vedanta Biosciences, Inc. as chair, BEFORE Brands, Inc., Crossover Health, Sanofi and GlaxoSmithKline. He is also the chair of the board of directors at Braveheart Bio, Inc., a trtee of Northeastern University and a member of the board of fellows at Stanford Medical School.Queen's University in Kingston, Ontario, Canada, B.A.- Christopher A. Viehbacher，Viehbacher先生自2022年11月起担任Biogen Inc.总裁兼首席执行官、Biogen Inc.董事会成员。在加入Biogen之前，Viehbacher先生曾于2015年至2022年担任总部位于波士顿的投资基金Gurnet Point Capital的管理合伙人。在此之前，Viehbacher先生于2008年至2014年担任赛诺菲全球首席执行官。在加入Sanofi之前，Viehbacher先生在德国、加拿大、法国的GlaxoSmithKline工作了20多年，后来又在美国担任北美制药部门的总裁。Viehbacher先生的职业生涯始于普华永道会计师事务所，并取得了特许会计师资格。Viehbacher先生曾在Vedanta Biosciences，Inc.、Before Brands，Inc.和Crossover Health担任董事会主席。他也是东北大学的董事和斯坦福医学院的研究员委员会成员。上市公司PureTech Health Plc董事会成员。教育，加拿大安大略省Queen's University学士。
- Christopher A. Viehbacher has served as President and Chief Executive Officer and member of Board of Directors since November 2022. Prior to joining Biogen, Mr. Viehbacher served as Managing Partner of Gurnet Point Capital, a Boston based investment fund from 2015 to 2022. Prior to that, Mr. Viehbacher served as Global CEO of Sanofi, from 2008 to 2014. Prior to joining Sanofi, Mr. Viehbacher spent over 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the U.S. as president of its North American pharmaceutical division. Mr. Viehbacher began his career with PricewaterhoeCoopers LLP and qualified as a chartered accountant. Mr. Viehbacher previoly served on the board of directors of Vedanta Biosciences, Inc. as chair, BEFORE Brands, Inc., Crossover Health, Sanofi and GlaxoSmithKline. He is also the chair of the board of directors at Braveheart Bio, Inc., a trtee of Northeastern University and a member of the board of fellows at Stanford Medical School.Queen's University in Kingston, Ontario, Canada, B.A.
- Robin C. Kramer
Robin C. Kramer，于2018年加入Biogen Inc.，自2020年12月起担任Biogen Inc.高级副总裁、首席会计官。在此之前，Kramer女士于2018年11月至2020年12月担任Biogen Inc.副总裁、首席会计官。在此职位上，她负责监督关键的财务职能，并领导公司的全球业务服务和财务部门。在加入公司之前，Kramer女士曾在Hertz Global Holdings, Inc.、Fisher Scientific International，Inc.和The Gillette Company担任高级财务职务，并曾是Deloitte & Touche LLP、Ernst & Young LLP和Arthur Andersen LLP的审计合伙人。Kramer女士目前担任Armata医药的董事会和审计委员会主席，并担任妇女与企业中心的董事会和财务委员会成员。她拥有Salem State大学会计学学士学位，是Commonwealth of Massachusetts的持牌注册会计师。
Robin C. Kramer has served as Chief Financial Officer since March 2025. Prior to that, Ms. Kramer served as Senior Vice President, Chief Accounting Officer from December 2020 to February 2025 and from November 2018 to December 2020 as Vice President, Chief Accounting Officer. Prior to joining Biogen, Ms. Kramer served as the Senior Vice President and Chief Accounting Officer of Hertz Global Holdings, Inc., a car rental company, from May 2014 to November 2018. Prior to that, Ms. Kramer was an audit partner at Deloitte & Touche LLP (Deloitte), a professional services firm, from 2007 to 2014, including serving in Deloitte's National Office Accounting Standards and Communications Group from 2007 to 2010. From 2005 to 2007 Ms. Kramer served as Chief Accounting Officer of Fisher Scientific International, Inc., a laboratory supply and biotechnology company, and from 2004 to 2005 Ms. Kramer served as Director, External Reporting, Accounting and Control for the Gillette Company, a personal care company. Ms. Kramer also held partner positions in the public accounting firms of Ernst & Young LLP and Arthur Andersen LLP. Ms. Kramer is a licensed CPA in Massachetts. She is a member of the Massachetts Society of CPAs and the American Institute of CPAs. Ms. Kramer previoly served as a Board Member for the Center for Women & Enterprise from Augt 2020 to November 2024, the Massachetts State Board of Accountancy from September 2011 to December 2015 and Prob Insurance Company Europe DAC from 2016 to 2018.Salem State University, B.S. Biness Administration, Accounting.- Robin C. Kramer，于2018年加入Biogen Inc.，自2020年12月起担任Biogen Inc.高级副总裁、首席会计官。在此之前，Kramer女士于2018年11月至2020年12月担任Biogen Inc.副总裁、首席会计官。在此职位上，她负责监督关键的财务职能，并领导公司的全球业务服务和财务部门。在加入公司之前，Kramer女士曾在Hertz Global Holdings, Inc.、Fisher Scientific International，Inc.和The Gillette Company担任高级财务职务，并曾是Deloitte & Touche LLP、Ernst & Young LLP和Arthur Andersen LLP的审计合伙人。Kramer女士目前担任Armata医药的董事会和审计委员会主席，并担任妇女与企业中心的董事会和财务委员会成员。她拥有Salem State大学会计学学士学位，是Commonwealth of Massachusetts的持牌注册会计师。
- Robin C. Kramer has served as Chief Financial Officer since March 2025. Prior to that, Ms. Kramer served as Senior Vice President, Chief Accounting Officer from December 2020 to February 2025 and from November 2018 to December 2020 as Vice President, Chief Accounting Officer. Prior to joining Biogen, Ms. Kramer served as the Senior Vice President and Chief Accounting Officer of Hertz Global Holdings, Inc., a car rental company, from May 2014 to November 2018. Prior to that, Ms. Kramer was an audit partner at Deloitte & Touche LLP (Deloitte), a professional services firm, from 2007 to 2014, including serving in Deloitte's National Office Accounting Standards and Communications Group from 2007 to 2010. From 2005 to 2007 Ms. Kramer served as Chief Accounting Officer of Fisher Scientific International, Inc., a laboratory supply and biotechnology company, and from 2004 to 2005 Ms. Kramer served as Director, External Reporting, Accounting and Control for the Gillette Company, a personal care company. Ms. Kramer also held partner positions in the public accounting firms of Ernst & Young LLP and Arthur Andersen LLP. Ms. Kramer is a licensed CPA in Massachetts. She is a member of the Massachetts Society of CPAs and the American Institute of CPAs. Ms. Kramer previoly served as a Board Member for the Center for Women & Enterprise from Augt 2020 to November 2024, the Massachetts State Board of Accountancy from September 2011 to December 2015 and Prob Insurance Company Europe DAC from 2016 to 2018.Salem State University, B.S. Biness Administration, Accounting.
- Rachid Izzar
Rachid Izzar，自2021年7月起担任阿尔茨海默氏病和痴呆症业务部的执行副总裁。在此之前，伊扎尔先生曾担任Biogen Inc.洲际地区的总裁，该地区包括拉丁美洲、澳大利亚、亚洲、日本、中东和非洲、土耳其和俄罗斯，以及全球生物原生物仿制药部门。在加入Biogen之前，伊扎尔是阿斯利康在法国的国家总裁，他的职责包括领导商业和制造业务。在阿斯利康任职期间，他担任过许多职务，包括心血管专营权的全球副总裁。在此之前，Izzar曾担任战略转型副总裁、上海首席执行官中国投资组合副总裁、中国、澳大利亚、巴西、俄罗斯、拉丁美洲、亚洲、土耳其、中东和非洲商业国际副总裁。舍布鲁克大学工商管理硕士。哈佛商学院，企业高管转型计划。
Rachid Izzar has served as Executive Vice President, Head of Global Product Strategy and Commercialization since July 2021. Prior to that Mr. Izzar served as President for the Intercontinental Region, which includes Latin America, Atralia, Asia, Japan, the Middle East and Africa, Turkey and Rsia, and the Global Biogen Biosimilars Unit. Prior to joining Biogen, Mr. Izzar was a Country President for AstraZeneca in France, where his responsibilities included leadership for commercial and manufacturing operations. He held numero roles at his time with AstraZeneca, including the position of Global Vice President of the Cardiovascular Franchise where he contributed significantly to the development of the franchise within the North American subsidiary, as ll as in Europe and China. Prior to that, Mr. Izzar was Vice President Strategic Transformation, also, China Portfolio for CEO based in Shanghai and Vice President Commercial International covering China, Atralia, Brazil, Rsia, America Latin, Asia, Turkey, the Middle East and Africa.University of Sherbrooke, Masters of Biness Administration,Harvard Biness School, Enterprise Executive Transformation Program.- Rachid Izzar，自2021年7月起担任阿尔茨海默氏病和痴呆症业务部的执行副总裁。在此之前，伊扎尔先生曾担任Biogen Inc.洲际地区的总裁，该地区包括拉丁美洲、澳大利亚、亚洲、日本、中东和非洲、土耳其和俄罗斯，以及全球生物原生物仿制药部门。在加入Biogen之前，伊扎尔是阿斯利康在法国的国家总裁，他的职责包括领导商业和制造业务。在阿斯利康任职期间，他担任过许多职务，包括心血管专营权的全球副总裁。在此之前，Izzar曾担任战略转型副总裁、上海首席执行官中国投资组合副总裁、中国、澳大利亚、巴西、俄罗斯、拉丁美洲、亚洲、土耳其、中东和非洲商业国际副总裁。舍布鲁克大学工商管理硕士。哈佛商学院，企业高管转型计划。
- Rachid Izzar has served as Executive Vice President, Head of Global Product Strategy and Commercialization since July 2021. Prior to that Mr. Izzar served as President for the Intercontinental Region, which includes Latin America, Atralia, Asia, Japan, the Middle East and Africa, Turkey and Rsia, and the Global Biogen Biosimilars Unit. Prior to joining Biogen, Mr. Izzar was a Country President for AstraZeneca in France, where his responsibilities included leadership for commercial and manufacturing operations. He held numero roles at his time with AstraZeneca, including the position of Global Vice President of the Cardiovascular Franchise where he contributed significantly to the development of the franchise within the North American subsidiary, as ll as in Europe and China. Prior to that, Mr. Izzar was Vice President Strategic Transformation, also, China Portfolio for CEO based in Shanghai and Vice President Commercial International covering China, Atralia, Brazil, Rsia, America Latin, Asia, Turkey, the Middle East and Africa.University of Sherbrooke, Masters of Biness Administration,Harvard Biness School, Enterprise Executive Transformation Program.
- Nicole Murphy
Nicole Murphy，自2022年2月起担任Biogen Inc.制药运营和技术执行副总裁。在此之前，Murphy女士曾在Biogen担任高级管理职务，最近于2019年6月至2022年1月担任Biogen Inc.高级副总裁兼全球制造与技术运营主管。2017年，Murphy女士在Biogen血友病专营权的成功分拆过程中发挥了关键作用，担任Bioverativ的副总裁兼技术运营主管，负责临床和商业开发、质量、监管、制造和采购。在分拆之前，Murphy女士于2015年5月至2016年12月担任百健公司的总经理兼剑桥网站运营主管。在加入Biogen之前，Murphy女士是生物制药公司Amgen的执行董事兼供应链主管，她的职责包括领导商业制造和技术运营。2001-2015年，Murphy女士在安进任职期间还担任过许多技术和业务职务，为各种设施初创企业、业务发展整合、战略转型和新产品推出做出了重大贡献。在加入安进公司之前，Murphy女士在Immunex制药公司和孟山都公司担任过各种工艺开发和工程职位。学历：Massachusetts Amherst大学B.S. Engineering分校，工学学士；伦斯勒理工学院，工学硕士，工商管理硕士。
Nicole Murphy has served as Executive Vice President, Pharmaceutical Operations and Technology since February 2022. Prior to that, Ms. Murphy has held senior executive positions at Biogen, including most recently as Senior Vice President, Head of Global Manufacturing & Technical Operations, from June 2019 to January 2022. In 2017, Ms. Murphy played a critical role during the successful spin off of Biogen's hemophilia franchise, as the Vice President and Head of Technical Operations of Bioverativ responsible for clinical and commercial development, quality, regulatory, manufacturing and procurement. Prior to the spin off Ms. Murphy was the General Manager and Head of Cambridge Site Operations at Biogen from May 2015 to December 2016. Prior to joining Biogen, Ms. Murphy was Executive Director, Head of Supply Chain at Amgen, a biopharmaceutical company, where her responsibilities included leadership of commercial manufacturing and technical operations. Ms. Murphy also held numero technical and operational roles during her time at Amgen from 2001 to 2015 where she contributed significantly to vario facility start ups, biness development integrations, strategic transformations and new product introductions. Prior to Amgen, Ms. Murphy held a variety of process development and engineering positions at Immunex Pharmaceuticals and the Monsanto Company.University of Massachetts Amherst, B.S. Engineering,Rensselaer Polytechnic Institute, M.S. Engineering and a Masters of Biness Administration.- Nicole Murphy，自2022年2月起担任Biogen Inc.制药运营和技术执行副总裁。在此之前，Murphy女士曾在Biogen担任高级管理职务，最近于2019年6月至2022年1月担任Biogen Inc.高级副总裁兼全球制造与技术运营主管。2017年，Murphy女士在Biogen血友病专营权的成功分拆过程中发挥了关键作用，担任Bioverativ的副总裁兼技术运营主管，负责临床和商业开发、质量、监管、制造和采购。在分拆之前，Murphy女士于2015年5月至2016年12月担任百健公司的总经理兼剑桥网站运营主管。在加入Biogen之前，Murphy女士是生物制药公司Amgen的执行董事兼供应链主管，她的职责包括领导商业制造和技术运营。2001-2015年，Murphy女士在安进任职期间还担任过许多技术和业务职务，为各种设施初创企业、业务发展整合、战略转型和新产品推出做出了重大贡献。在加入安进公司之前，Murphy女士在Immunex制药公司和孟山都公司担任过各种工艺开发和工程职位。学历：Massachusetts Amherst大学B.S. Engineering分校，工学学士；伦斯勒理工学院，工学硕士，工商管理硕士。
- Nicole Murphy has served as Executive Vice President, Pharmaceutical Operations and Technology since February 2022. Prior to that, Ms. Murphy has held senior executive positions at Biogen, including most recently as Senior Vice President, Head of Global Manufacturing & Technical Operations, from June 2019 to January 2022. In 2017, Ms. Murphy played a critical role during the successful spin off of Biogen's hemophilia franchise, as the Vice President and Head of Technical Operations of Bioverativ responsible for clinical and commercial development, quality, regulatory, manufacturing and procurement. Prior to the spin off Ms. Murphy was the General Manager and Head of Cambridge Site Operations at Biogen from May 2015 to December 2016. Prior to joining Biogen, Ms. Murphy was Executive Director, Head of Supply Chain at Amgen, a biopharmaceutical company, where her responsibilities included leadership of commercial manufacturing and technical operations. Ms. Murphy also held numero technical and operational roles during her time at Amgen from 2001 to 2015 where she contributed significantly to vario facility start ups, biness development integrations, strategic transformations and new product introductions. Prior to Amgen, Ms. Murphy held a variety of process development and engineering positions at Immunex Pharmaceuticals and the Monsanto Company.University of Massachetts Amherst, B.S. Engineering,Rensselaer Polytechnic Institute, M.S. Engineering and a Masters of Biness Administration.
- Priya Singhal
Priya Singhal，医学博士，硕士经验Singhal博士自2023年1月起担任Biogen Inc.执行副总裁兼开发部主管。在此之前，Singhal博士自2021年起担任Biogen Inc.临时研发主管，自2020年重新加入Biogen以来，她还担任包括中国和日本研发在内的全球安全和监管科学主管。Singhal博士最初于2012年至2018年在Biogen任职，历任临床试验效益风险管理副总裁、安全和效益风险管理全球主管、全球发展临时联席主管和高级副总裁等职位。在2020年重返Biogen之前，Singhal博士曾于2019年至2020年在Zafgen Inc.担任研发和制造主管。2008年至2012年，Singhal博士在Vertex制药公司任职，包括医疗事务副总裁。Singhal博士于2005年在Millennium Pharmaceuticals，Inc.开始了她的药物开发生涯，并领导了Velcade和其他化合物的效益风险管理。教育：哈佛公共卫生学院，国际卫生Mumbaii大学硕士，医学博士（医学博士）。
Priya Singhal has served as Executive Vice President and Head of Development since January 2023. Prior to that Dr. Singhal served as Interim Head of Research and Development since 2021 in addition to serving as Head of Global Safety and Regulatory Sciences, including China and Japan Research and Development, since rejoining Biogen in 2020. Dr. Singhal was initially at Biogen from 2012 to 2018 and served in positions of increasing seniority as Vice President Clinical Trials Benefit Risk Management, Global Head of Safety and Benefit Risk Management and as the Interim Co lead and Senior Vice President of Global Development. Prior to her 2020 return to Biogen, Dr. Singhal served as Head of Research and Development and Manufacturing at Zafgen Inc. from 2019 to 2020. From 2008 to 2012 Dr. Singhal held roles at Vertex Pharmaceuticals, including Vice President, Medical Affairs. Dr. Singhal began her drug development career at Millennium Pharmaceuticals, Inc. in 2005 and led benefit risk management for Velcade and other compounds.Harvard School of Public Health, M.P.H. in International Health,University of Mumbai, Doctor of Medicine (M.D.).- Priya Singhal，医学博士，硕士经验Singhal博士自2023年1月起担任Biogen Inc.执行副总裁兼开发部主管。在此之前，Singhal博士自2021年起担任Biogen Inc.临时研发主管，自2020年重新加入Biogen以来，她还担任包括中国和日本研发在内的全球安全和监管科学主管。Singhal博士最初于2012年至2018年在Biogen任职，历任临床试验效益风险管理副总裁、安全和效益风险管理全球主管、全球发展临时联席主管和高级副总裁等职位。在2020年重返Biogen之前，Singhal博士曾于2019年至2020年在Zafgen Inc.担任研发和制造主管。2008年至2012年，Singhal博士在Vertex制药公司任职，包括医疗事务副总裁。Singhal博士于2005年在Millennium Pharmaceuticals，Inc.开始了她的药物开发生涯，并领导了Velcade和其他化合物的效益风险管理。教育：哈佛公共卫生学院，国际卫生Mumbaii大学硕士，医学博士（医学博士）。
- Priya Singhal has served as Executive Vice President and Head of Development since January 2023. Prior to that Dr. Singhal served as Interim Head of Research and Development since 2021 in addition to serving as Head of Global Safety and Regulatory Sciences, including China and Japan Research and Development, since rejoining Biogen in 2020. Dr. Singhal was initially at Biogen from 2012 to 2018 and served in positions of increasing seniority as Vice President Clinical Trials Benefit Risk Management, Global Head of Safety and Benefit Risk Management and as the Interim Co lead and Senior Vice President of Global Development. Prior to her 2020 return to Biogen, Dr. Singhal served as Head of Research and Development and Manufacturing at Zafgen Inc. from 2019 to 2020. From 2008 to 2012 Dr. Singhal held roles at Vertex Pharmaceuticals, including Vice President, Medical Affairs. Dr. Singhal began her drug development career at Millennium Pharmaceuticals, Inc. in 2005 and led benefit risk management for Velcade and other compounds.Harvard School of Public Health, M.P.H. in International Health,University of Mumbai, Doctor of Medicine (M.D.).
- Jane Grogan
Jane Grogan，自2023年9月起担任Biogen Inc.执行副总裁兼开发主管。Grogan博士最近于2021-2023年在Graphite Bio担任首席科学官，于2019-2021年在ArsenalBio担任首席科学官，这两家公司都是细胞和基因治疗公司。从2004年到2019年，Grogan博士在基因泰克的免疫学和免疫肿瘤学领域担任过多个职位，负责提高资历，涵盖类风湿性关节炎、狼疮、MS、炎症性肠病和癌症领域的研究策略和药物开发。
Jane Grogan has served as Executive Vice President and Head of Development since October 2023. Dr. Grogan most recently served as the Chief Scientific Officer at Graphite Bio from 2021 to 2023 and ArsenalBio from 2019 to 2021, both cell and gene therapy companies. From 2004 to 2019 Dr. Grogan held several roles in increasing seniority at Genentech across Immunology and Immuno oncology, covering research strategies and drug development across Rheumatoid Arthritis, Lup, MS, Inflammatory Bol Disease and Cancer.Leiden University, Ph.D. in Immunology,University of Melbne, B.Sc in Biochemistry and Pharmacology.- Jane Grogan，自2023年9月起担任Biogen Inc.执行副总裁兼开发主管。Grogan博士最近于2021-2023年在Graphite Bio担任首席科学官，于2019-2021年在ArsenalBio担任首席科学官，这两家公司都是细胞和基因治疗公司。从2004年到2019年，Grogan博士在基因泰克的免疫学和免疫肿瘤学领域担任过多个职位，负责提高资历，涵盖类风湿性关节炎、狼疮、MS、炎症性肠病和癌症领域的研究策略和药物开发。
- Jane Grogan has served as Executive Vice President and Head of Development since October 2023. Dr. Grogan most recently served as the Chief Scientific Officer at Graphite Bio from 2021 to 2023 and ArsenalBio from 2019 to 2021, both cell and gene therapy companies. From 2004 to 2019 Dr. Grogan held several roles in increasing seniority at Genentech across Immunology and Immuno oncology, covering research strategies and drug development across Rheumatoid Arthritis, Lup, MS, Inflammatory Bol Disease and Cancer.Leiden University, Ph.D. in Immunology,University of Melbne, B.Sc in Biochemistry and Pharmacology.
- Adam Keeney
Adam Keeney，自2023年4月起担任Biogen Inc.执行副总裁兼企业发展主管。Keeney博士最近担任NodThera的首席执行官，NodThera是一家临床阶段的生物技术公司，2018年至2022年专注于慢性炎症。在加入NodThera之前，Keeney博士于2014年至2018年在赛诺菲任职，负责赛诺菲 Gezyme的所有业务发展活动，包括跨治疗领域和模式的早期和后期交易，成功完成了几笔重大交易。从2004年到2013年，Keeney博士曾在强生工作，担任过多个责任越来越大的业务发展职务，并在Lundbeck以发现科学家的身份开始了他的职业生涯。
Adam Keeney has served as Executive Vice President and Head of Corporate Development since April 2023. Dr. Keeney most recently served as the Chief Executive Officer of NodThera, a clinical stage biotech company foced on chronic inflammation from 2018 to 2022. Prior to NodThera, Dr. Keeney was at Sanofi from 2014 to 2018 where he had responsibility for all of Sanofi Genzyme's biness development activities, including early and late stage deals across therapeutic areas and modalities, successfully completing several significant transactions. From 2004 to 2013 Dr. Keeney worked at Johnson & Johnson where he held a number of biness development roles with increasing responsibility and started his career at Lundbeck as a discovery scientist.University of Nottingham, UK, Ph.D. in Neuropharmacology,University of Leeds, UK, BSc (Hons).- Adam Keeney，自2023年4月起担任Biogen Inc.执行副总裁兼企业发展主管。Keeney博士最近担任NodThera的首席执行官，NodThera是一家临床阶段的生物技术公司，2018年至2022年专注于慢性炎症。在加入NodThera之前，Keeney博士于2014年至2018年在赛诺菲任职，负责赛诺菲 Gezyme的所有业务发展活动，包括跨治疗领域和模式的早期和后期交易，成功完成了几笔重大交易。从2004年到2013年，Keeney博士曾在强生工作，担任过多个责任越来越大的业务发展职务，并在Lundbeck以发现科学家的身份开始了他的职业生涯。
- Adam Keeney has served as Executive Vice President and Head of Corporate Development since April 2023. Dr. Keeney most recently served as the Chief Executive Officer of NodThera, a clinical stage biotech company foced on chronic inflammation from 2018 to 2022. Prior to NodThera, Dr. Keeney was at Sanofi from 2014 to 2018 where he had responsibility for all of Sanofi Genzyme's biness development activities, including early and late stage deals across therapeutic areas and modalities, successfully completing several significant transactions. From 2004 to 2013 Dr. Keeney worked at Johnson & Johnson where he held a number of biness development roles with increasing responsibility and started his career at Lundbeck as a discovery scientist.University of Nottingham, UK, Ph.D. in Neuropharmacology,University of Leeds, UK, BSc (Hons).
- Sean Godbout
Sean Godbout，于2007年加入公司，自2023年10月起担任全球公司财务总监。在担任这一职务之前，Godbout先生于2019年9月至2023年10月担任公司财务总监，自2007年以来一直在公司担任越来越多的职责。在加入渤健之前，Godbout先生曾在普华永道会计师事务所任职。他拥有康奈尔大学工业与劳动关系学士学位和东北大学会计学硕士和MBA学位。Godbout先生是马萨诸塞州的注册会计师。
Sean Godbout has served as Vice President, Chief Accounting Officer and Global Corporate Controller since March 2025. Prior to that, Mr. Godbout served as Global Corporate Controller from October 2023 to February 2025 and Corporate Controller from September 2019 to October 2023 and has held roles of increasing seniority at the Company since 2007. Prior to joining Biogen, Mr. Godbout spent 10 years at PricewaterhoeCoopers LLP and he is a licensed CPA.Cornell University, B.S. Indtrial and labor Relations,Northeastern University, M.S. Accounting and Masters of Biness Administration.- Sean Godbout，于2007年加入公司，自2023年10月起担任全球公司财务总监。在担任这一职务之前，Godbout先生于2019年9月至2023年10月担任公司财务总监，自2007年以来一直在公司担任越来越多的职责。在加入渤健之前，Godbout先生曾在普华永道会计师事务所任职。他拥有康奈尔大学工业与劳动关系学士学位和东北大学会计学硕士和MBA学位。Godbout先生是马萨诸塞州的注册会计师。
- Sean Godbout has served as Vice President, Chief Accounting Officer and Global Corporate Controller since March 2025. Prior to that, Mr. Godbout served as Global Corporate Controller from October 2023 to February 2025 and Corporate Controller from September 2019 to October 2023 and has held roles of increasing seniority at the Company since 2007. Prior to joining Biogen, Mr. Godbout spent 10 years at PricewaterhoeCoopers LLP and he is a licensed CPA.Cornell University, B.S. Indtrial and labor Relations,Northeastern University, M.S. Accounting and Masters of Biness Administration.
- Susan H. Alexander
Susan H. Alexander，经验丰富，Alexander女士自2018年4月起担任Biogen Inc.执行副总裁、首席法务官兼秘书。在此之前，Alexander女士于2017年3月至2018年3月担任Biogen Inc.执行副总裁、首席法律、企业服务兼秘书，于2011年12月至2017年3月担任Biogen Inc.执行副总裁、首席法律官兼秘书，于2006年至2011年12月担任Biogen Inc.执行副总裁、总法律顾问兼公司秘书。在加入Biogen之前，Alexander女士曾于2003年至2006年1月担任生物制药服务公司Parexel International Corporation的高级副总裁、总法律顾问和公司秘书。2001年至2003年，Alexander女士担任软件公司IONA Technologies的总法律顾问。1995年至2001年，Alexander女士在Cabot Corporation一家特殊化学品和性能材料公司担任法律顾问。在此之前，Alexander女士是Hinckley，Allen & Snyder和Fine & Ambrogne律师事务所的合伙人。教育：韦尔斯利学院学士，波士顿大学法学院，法学博士。
Susan H. Alexander has served as Executive Vice President, Chief Legal Officer since April 2018. Prior to that, Ms. Alexander served as Executive Vice President, Chief Legal and Corporate Services from March 2017 to March 2018, as Executive Vice President, Chief Legal Officer and Secretary from December 2011 to March 2017 and as Executive Vice President, General Counsel and Corporate Secretary from 2006 to December 2011. Prior to joining Biogen, Ms. Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corporation, a biopharmaceutical services company, from 2003 to January 2006. From 2001 to 2003 Ms. Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001 Ms. Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials company. Prior to that, Ms. Alexander was a partner at the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne.llesley College, B.A.Boston University School of Law, J.D.- Susan H. Alexander，经验丰富，Alexander女士自2018年4月起担任Biogen Inc.执行副总裁、首席法务官兼秘书。在此之前，Alexander女士于2017年3月至2018年3月担任Biogen Inc.执行副总裁、首席法律、企业服务兼秘书，于2011年12月至2017年3月担任Biogen Inc.执行副总裁、首席法律官兼秘书，于2006年至2011年12月担任Biogen Inc.执行副总裁、总法律顾问兼公司秘书。在加入Biogen之前，Alexander女士曾于2003年至2006年1月担任生物制药服务公司Parexel International Corporation的高级副总裁、总法律顾问和公司秘书。2001年至2003年，Alexander女士担任软件公司IONA Technologies的总法律顾问。1995年至2001年，Alexander女士在Cabot Corporation一家特殊化学品和性能材料公司担任法律顾问。在此之前，Alexander女士是Hinckley，Allen & Snyder和Fine & Ambrogne律师事务所的合伙人。教育：韦尔斯利学院学士，波士顿大学法学院，法学博士。
- Susan H. Alexander has served as Executive Vice President, Chief Legal Officer since April 2018. Prior to that, Ms. Alexander served as Executive Vice President, Chief Legal and Corporate Services from March 2017 to March 2018, as Executive Vice President, Chief Legal Officer and Secretary from December 2011 to March 2017 and as Executive Vice President, General Counsel and Corporate Secretary from 2006 to December 2011. Prior to joining Biogen, Ms. Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corporation, a biopharmaceutical services company, from 2003 to January 2006. From 2001 to 2003 Ms. Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001 Ms. Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials company. Prior to that, Ms. Alexander was a partner at the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne.llesley College, B.A.Boston University School of Law, J.D.
- Ginger Gregory
Ginger Gregory，经验丰富的博士Gregory博士自2017年7月起担任Biogen Inc.执行副总裁兼首席人力资源官。在加入Biogen之前，Gregory博士于2014年2月至2017年4月在全球专业生物制药公司Shire PLC担任执行副总裁兼首席人力资源官。在此之前，Gregory博士曾在多个各行各业的跨国公司担任高管级别的人力资源职位，包括餐饮控股公司Dunkin ' Brands Group Inc.，在制药公司Novartis AG担任首席人力资源官，在制药公司诺华疫苗和诊断、诺华消费者健康和诺华生物医学研究所以及制药公司Novo Nordisk A/S担任人力资源部门负责人，并在公司总部丹麦Copenhagen担任企业人事与组织高级副总裁。在她职业生涯的早期，Gregory博士在制药公司BMS担任过各种人力资源通才和专家职位，并在信息技术咨询公司Booz Allen & Hamilton担任组织变革和效率领域的顾问。教育，Massachusetts，心理学学士；乔治华盛顿大学，心理学博士。
Ginger Gregory has served as Executive Vice President and Chief Human Resces Officer since July 2017. Prior to joining Biogen, Dr. Gregory served as Executive Vice President and Chief Human Resces Officer at Shire PLC, a global specialty biopharmaceutical company, from February 2014 to April 2017. Prior to that, Dr. Gregory held executive level human resces positions for several multinational companies across a variety of indtries, including Dunkin' Brands Group Inc., a restaurant holding company, where she served as Chief Human Resce Officer, Novartis AG, a pharmaceutical company, where she was the division head of Human Resces for Novartis Vaccines and Diagnostics, Novartis Consumer Health and Novartis Institutes of BioMedical Research and Novo Nordisk A/S, a pharmaceutical company, where she served as Senior Vice President, Corporate People & Organization at the company's headquarters in Copenhagen, Denmark. Earlier in her career, Dr. Gregory held a variety of human resces generalist and specialist positions at BMS, a pharmaceutical company, and served as a consultant with Booz Allen & Hamilton, an information technology consulting company, in the area of organization change and effectiveness. University of Massachetts, B.A. Psychology,The George Washington University, Ph.D. Psychology.- Ginger Gregory，经验丰富的博士Gregory博士自2017年7月起担任Biogen Inc.执行副总裁兼首席人力资源官。在加入Biogen之前，Gregory博士于2014年2月至2017年4月在全球专业生物制药公司Shire PLC担任执行副总裁兼首席人力资源官。在此之前，Gregory博士曾在多个各行各业的跨国公司担任高管级别的人力资源职位，包括餐饮控股公司Dunkin ' Brands Group Inc.，在制药公司Novartis AG担任首席人力资源官，在制药公司诺华疫苗和诊断、诺华消费者健康和诺华生物医学研究所以及制药公司Novo Nordisk A/S担任人力资源部门负责人，并在公司总部丹麦Copenhagen担任企业人事与组织高级副总裁。在她职业生涯的早期，Gregory博士在制药公司BMS担任过各种人力资源通才和专家职位，并在信息技术咨询公司Booz Allen & Hamilton担任组织变革和效率领域的顾问。教育，Massachusetts，心理学学士；乔治华盛顿大学，心理学博士。
- Ginger Gregory has served as Executive Vice President and Chief Human Resces Officer since July 2017. Prior to joining Biogen, Dr. Gregory served as Executive Vice President and Chief Human Resces Officer at Shire PLC, a global specialty biopharmaceutical company, from February 2014 to April 2017. Prior to that, Dr. Gregory held executive level human resces positions for several multinational companies across a variety of indtries, including Dunkin' Brands Group Inc., a restaurant holding company, where she served as Chief Human Resce Officer, Novartis AG, a pharmaceutical company, where she was the division head of Human Resces for Novartis Vaccines and Diagnostics, Novartis Consumer Health and Novartis Institutes of BioMedical Research and Novo Nordisk A/S, a pharmaceutical company, where she served as Senior Vice President, Corporate People & Organization at the company's headquarters in Copenhagen, Denmark. Earlier in her career, Dr. Gregory held a variety of human resces generalist and specialist positions at BMS, a pharmaceutical company, and served as a consultant with Booz Allen & Hamilton, an information technology consulting company, in the area of organization change and effectiveness. University of Massachetts, B.A. Psychology,The George Washington University, Ph.D. Psychology.